handshake-istock-512549722-choreograph-

Choreograph / iStockphoto.com

27 April 2017Americas

Merck to pay PDL $19.5m in settlement agreement

Merck and PDL Biopharma have settled a dispute over Merck’s cancer drug Keytruda (pembrolizumab), which allegedly infringed a patent belonging to PDL.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent